Table 1.
Baseline characteristics of the training and test set populations (case and control)1.
Figure 1.
Work flow used for the determination of urinary biomarkers associated with RA.
Table 2.
Urinary peptides which were significantly less abundant in patients with RA.
Table 3.
Urinary peptides which were found in significantly higher concentration in patients with RA.
Figure 2.
Urinary polypeptide signatures in cases and controls from the validation set based on 39 significantly different sequenced peptides.
Normalized molecular weight (500–15000 Da) in logarithmic scale is plotted against normalized migration time (18–45 minutes). The mean signal intensity of the polypeptide peak is given in 3-dimensional depiction (n = 15 controls and 16 cases).
Figure 3.
Graphical representation of the frequency distribution of proteases with modified activity associated with RA.
Percentage frequency of peptide occurrences in the down-regulation group is plotted on the x-axis, whereas the percentage frequency of occurrences in the up-regulated group is plotted on the y-axis. Circled data points represent the proteases which activity is the most affected in RA compared to that of healthy controls (see Table 4).
Table 4.
Predictive analysis of changes in protease activity associated with peptides differentially regulated in RA 1.